Jess Marden
Boston
Education
Sc.D., social epidemiology, Harvard T.H. Chan School of Public Health; M.P.H., epidemiology and biostatistics, Tufts University School of Medicine; B.A., international relations, Tufts University
Summary of Experience
Dr. Marden specializes in applying tools from epidemiology and biostatistics to health economics and outcomes research (HEOR) questions. She has experience applying novel epidemiologic methods to multiple disease areas, including rare diseases, multiple types of cancer, and neurological and cardiovascular diseases. Her work includes estimating the burden of illness from claims data, prospectively collecting natural history data to inform trial design and the understanding of disease progression, estimating the comparative efficacy of alternative therapies, and analyzing treatment patterns. Prior to joining Analysis Group, Dr. Marden was a postdoctoral research fellow at the Broad Institute of MIT and Harvard.
Selected Publishing
-
Maralixibat Treatment Response in Alagille Syndrome Is Associated with Improved Health-Related Quality of Life
The Journal of Pediatrics, 2022
2022Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E
-
Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center
Journal of Comparative Effectiveness Research, 2020
2020Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL
-
Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding
Annals of Epidemiology, 2019
2019Glymour MM, Gibbons LE, Gilsanz P, Gross AL, Mez J, Brewster PW, Marden J, Zahodne LB, Nho K, Hamilton J, Li G, Larson EB, Crane PK